BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Alder Biopharmaceuticals Inc. Appoints Bruce Montgomery to Board of Directors


11/1/2010 10:27:49 AM

BOTHELL, Wash., Nov. 1, 2010 /PRNewswire/ -- Alder Biopharmaceuticals Inc. today announced that it has appointed A. Bruce Montgomery, M.D., to the company's board of directors.

Dr. Montgomery, 57, served as founder and chief executive officer of Corus Pharmaceuticals from 2001 through its acquisition in 2006 by Gilead Sciences. While at Gilead, he served as Senior Vice President and Head of Respiratory Therapeutics where he successfully led the approval of Cayston (aztreonam) as a treatment to improve respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa. He previously held positions in clinical development with PathoGenesis and Genentech. Dr. Montgomery recently served on the board of directors for Zymogenetics and is a trustee of the Washington State Life Sciences Fund.

"Bruce brings a wealth of global pharmaceutical and biotechnology industry experience to the Alder board including his involvement with a number of drug approvals," said Randall Schatzman, president and chief executive officer of Alder Biopharmaceuticals. "We look forward to his contributions as Alder continues to grow its pipeline of clinical assets and move ALD518 through clinical studies in cancer, cancer anemia and cancer supportive care."

Dr. Montgomery received a bachelor's degree in chemistry and a doctorate from University of Washington. He completed postgraduate training at University of Washington and University of California, San Francisco.

About Alder Biopharmaceuticals

Alder Biopharmaceuticals Inc. uniquely identifies, develops and manufactures novel antibody therapeutics to alleviate human suffering in the autoimmune and inflammatory disease areas. Alder's management team combines decades of industry experience with a proven track record for identifying and developing novel antibody therapeutics and enabling partners through the out-licensing of its technologies. In addition to Bristol-Myers Squibb, partners include Merck (Schering-Plough), Seattle Genetics and Genmab. For more information, visit www.alderbio.com.

Media Contact:

Ian Stone or David Schull

Russo Partners

Tel: +1 619-528-2220

ian.stone@russopartnersllc.com

david.schull@russopartnersllc.com



SOURCE Alder Biopharmaceuticals Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES